Ruth Duncan

Sort by:

Ruth Duncan, Rogério S Gaspar
Molecular pharmaceutics
2011

Depending on the context, nanotechnologies developed as nanomedicines (nanosized therapeutics and imaging agents) are presented as either a remarkable technological revolution already capable of… (More)

Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo.

Namita Malik, Ruedeekorn Wiwattanapatapee, +6 authors Ruth Duncan
Journal of controlled release : official journal…
2000

Dendrimers are highly branched macromolecules of low polydispersity that provide many exciting opportunities for design of novel drug-carriers, gene delivery systems and imaging agents. They hold… (More)

Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: opportunities and challenges.

Ruth Duncan, Simon Richardson
Molecular pharmaceutics
2012

More than 40 nanomedicines are already in routine clinical use with a growing number following in preclinical and clinical development. The therapeutic objectives are often enhanced disease-specific… (More)

Dendrimer biocompatibility and toxicity.

Ruth Duncan, Lorella Izzo
Advanced drug delivery reviews
2005

The field of biomedical dendrimers is still in its infancy, but the explosion of interest in dendrimers and dendronised polymers as inherently active therapeutic agents, as vectors for targeted… (More)

Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation

Sunil Shaunak, Sharyn Thomas, +9 authors Steve Brocchini
Nature Biotechnology
2004

Dendrimers are hyperbranched macromolecules that can be chemically synthesized to have precise structural characteristics. We used anionic, polyamidoamine, generation 3.5 dendrimers to make novel… (More)

Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics.

Rogério S Gaspar, Ruth Duncan
Advanced drug delivery reviews
2009

Since the early 1990s polymer-protein conjugates (included PEGylated enzymes and cytokines), polymeric drugs and polymeric sequestrants have been entering the market as innovative polymer-based… (More)

Heterogeneous nuclear ribonucleoprotein A1 binds to the transcription-regulatory region of mouse hepatitis virus RNA.

Hongwei Li, Xiaofeng Zhang, Ruth Duncan, Luca Comai, Michael M C Lai
Proceedings of the National Academy of Sciences…
1997

A cellular protein, previously described as p35/38, binds to the complementary (-)-strand of the leader RNA and intergenic (IG) sequence of mouse hepatitis virus (MHV) RNA. The extent of the binding… (More)

Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic.

Ruth Duncan, Stéphanie Gac-Breton, +4 authors F Searle
Journal of controlled release : official journal…
2001

There are now at least seven polymer-drug conjugates that have entered phase I/II clinical trial as anticancer agents. These include N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-doxorubicin… (More)

Polymer therapeutics-prospects for 21st century: the end of the beginning.

Ruth Duncan, Maria Jesus Vicent
Advanced drug delivery reviews
2013

The term "polymer therapeutics" was coined to describe polymeric drugs, polymer conjugates of proteins, drugs and aptamers, together with those block copolymer micelles and multicomponent non-viral… (More)

PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.

Francesco Maria Veronese, Oddone Schiavon, +8 authors Ruth Duncan
Bioconjugate chemistry
2005

Polymer-drug conjugates (polymer therapeutics) are finding increasing use as novel anticancer agents. Here a series of poly(ethylene glycol) PEG-doxorubicin (Dox) conjugates were synthesized using… (More)

Filter Results:

Publication Year

Publication Type

Co-author

Journals and Conferences